This randomized, interventional study examines the effects of short-term carbohydrate restriction, with and without caloric restriction, on indices of metabolic flexibility in healthy adults. Participants are randomly assigned to either a low-carbohydrate diet or a standard diet under energy balance, followed by the same diet under controlled caloric restriction. Primary outcomes include measures of carbon dioxide production, breath ketones and interstitial glucose. Secondary outcomes include blood and urinary ketones, body weight, body composition, and selected metabolic biomarkers.
This is a monocentric, randomized, open-label nutrition intervention conducted in healthy adults aged 18 to 40 years. The study investigates the effects of short-term carbohydrate and caloric restriction on indices of metabolic flexibility. After screening and baseline assessments, participants undergo an initial period of energy balance with a standardized diet, followed by a 2-week intervention phase. Participants are randomly assigned in a 1:1 ratio to either a low-carbohydrate diet or a standard mixed diet. Participants are instructed to maintain their habitual physical activity throughout the study. During the first week of the intervention period, energy intake is equivalent to estimated energy requirements. During the second week, energy intake is reduced by \~500 kcal/d. Metabolic outcomes are assessed using repeated laboratory and remote measurements. Primary outcomes include breath-based measures of carbon dioxide and acetone production, as well as continuous glucose monitoring. Secondary outcomes include urinary and capillary blood ketones, body weight, body composition, resting metabolic rate, plasma glucose and selected biomarkers (leptin, insulin, triiodothyronine, GLP-1, HbA1c). Data are collected at baseline, during the intervention, and post-intervention. The total participation time per participant is approximately three weeks. The study aims to characterize short-term metabolic responses to dietary carbohydrate manipulation and energy deficit under controlled conditions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
Participants receive a low-carbohydrate diet. All meals are provided and individually tailored based on estimated energy requirements. Carbohydrate intake is restricted to 75-125 g per day, with the remaining energy intake derived from fat and protein. The intervention is administered for 14 days.
Participants receive a standard mixed diet. All meals are provided and individually tailored based on estimated energy requirements. The macronutrient distribution consists of approximately 50-55% carbohydrates, 25-35% fat, and 15% protein. The intervention is administered for 14 days.
Technical University of Munich
München, Bavaria, Germany
Carbon dioxide production and breath acetone concentration
Carbon dioxide production and breath acetone concentration are assessed using portable breath analysis devices during standardized daily measurements and timepoints.
Time frame: Baseline, during the energy-deficit intervention period, and post-intervention (over approximately 3 weeks)
Interstitial glucose concentration assessed by continuous glucose monitoring
Continuous glucose monitoring is used to assess interstitial glucose concentration, including average glucose levels, glucose variability, and time in glycemic ranges.
Time frame: Continuously assessed throughout the study period (approximately 3 weeks)
Urinary ketone concentration
Urinary ketone concentration is assessed once daily using reagent test strips and self-reported by participants.
Time frame: Daily during the study period (approximately 3 weeks)
Capillary blood ketone concentration
Capillary blood ketone concentration is measured once daily in the fasting state using a handheld ketone meter.
Time frame: Daily during the study period (approximately 3 weeks)
Fasting capillary blood glucose concentration
Fasting blood glucose concentration is measured once daily using a capillary blood glucose meter.
Time frame: Daily during the study period (approximately 3 weeks)
Body weight
Body weight is measured daily using a Bluetooth-enabled electronic scale.
Time frame: Daily during the study period (approximately 3 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
NONE
Enrollment
30
Fat Mass
Fat mass is assessed using bioelectrical impedance analysis and air displacement plethysmography.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)
Fat-Free Mass
Fat-free mass is assessed using bioelectrical impedance analysis and air displacement plethysmography.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)
Body Fat Percentage
Body fat percentage is assessed using bioelectrical impedance analysis and air displacement plethysmography.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)
Resting metabolic rate
Resting metabolic rate is assessed by indirect calorimetry during laboratory visits.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)
Plasma Leptin Concentration
Blood samples are collected to assess plasma leptin concentration.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)
Plasma Insulin Concentration
Blood samples are collected to assess plasma insulin concentration.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)
Plasma Triiodothyronine (T3) Concentration
Blood samples are collected to assess plasma triiodothyronine (T3) concentration.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)
Plasma Glucagon-Like Peptide-1 (GLP-1) Concentration
Blood samples are collected to assess plasma glucagon-like peptide-1 (GLP-1) concentration.
Time frame: Baseline (Day 1), mid-intervention (approximately Day 14), and post-intervention (approximately Day 21)